Intellia (NTLA) Stock: Citigroup Reiterates 'Outperform' on BLA

Intellia Therapeutics (NASDAQ:NTLA) Stock Analysis: Citigroup Reiterates 'Outperform' Amid BLA Submission

Intellia Therapeutics (NASDAQ:NTLA) is advancing its CRISPR gene editing therapy, lonvo-z, for hereditary angioedema (HAE).

Citigroup reiterated an "Outperform" rating for Intellia Therapeutics, with the stock price at $13.04.

The biotechnology company is pursuing FDA approval for lonvo-z following positive Phase 3 trial results and announced a $150 million public offering.

Intellia Therapeutics (NASDAQ:NTLA) is a biotechnology company that develops treatments using CRISPR gene editing technology. Its main activities involve creating therapies for genetic diseases. A key drug candidate is lonvo-z, which is being developed as a potential one-time treatment for a rare condition called hereditary angioedema (HAE).

On April 28, 2026, Citigroup reiterated its "Outperform" rating for Intellia Therapeutics. An "Outperform" rating means the analyst believes the stock will likely provide returns that are better than the overall market. At the time of this rating, the stock price was $13.04 amid several major company announcements.

This rating follows positive news about the company's drug development. Intellia Therapeutics has initiated a rolling Biologics License Application (BLA) with the U.S. Food and Drug Administration for lonvo-z. A BLA is a formal request to get FDA approval to sell a new biological drug in the United States.

The BLA submission is supported by successful Phase 3 trial results. The trial showed that a single dose of lonvo-z was effective in preventing HAE attacks. At the same time, Intellia Therapeutics announced a proposed public offering to raise $150 million by selling new shares of its common stock.

Despite the positive trial data, Intellia Therapeutics' stock price is $13.04, a decrease of 4.33% for the day. The company has a market capitalization of about $1.54 billion. Market capitalization is the total market value of a company's outstanding shares. The stock's price has ranged from $6.83 to $28.25 over the past year.